AKT1 and acute myeloid leukemia: The addition of Venetoclax to the therapeutic regimens may be of particular interest in p-Akt positive patients because it is known that Akt upregulates Bcl-2 expression [30] Beside the Venetoclax [110], BP1002, a liposomal Bcl-2 antisense oligodeoxynucleotide [111] is still available now in a clinical trial for AML patients.